• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Gonadotropin-releasing hormone analogs protect against premature ovarian insufficiency in breast-cancer patients treated with chemotherapy

byKassandra McFarlaneandSze Wah Samuel Chan
January 10, 2022
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The chemotherapy-only treatment group had a greater number of patients with premature ovarian insufficiency

2. Overall survival and tumour-free survival were higher in patients under 35 years old who were receiving chemotherapy with adjunct GnRHa

Evidence Rating Level: 1 (Excellent)

Study Rundown: The role of gonadtropin-releasing hormone analogs (GnRHa) for preserving ovarian function during treatment for breast cancer with chemotherapy is unclear. This study explored the impact of adjunct GnRHa on adult premenopausal female patients with breast cancer being treated with chemotherapy. The primary outcome was the rate of premature ovarian insufficiency (POI) at one year after chemotherapy, as determined by anti-MĂĽlllerian hormone (AMH) levels of 0.5ng/mL or less. Secondary outcomes included overall survival (OS) and tumour-free survival (TFS). 345 women were randomly allocated in a 1:1 ratio to receive chemotherapy with or without GnRHa; 330 were included in the primary analysis. There were significantly more women in the chemotherapy-only group as compared to the GnRHa group who were identified as having POI at one year. There were no significant differences between the two groups for OS or TFS at 4 years, but there were significantly better outcomes for both measures in the GnRHa group when considering patients less than 35 years old. Limitations to this study include unclear applications to fertility after chemotherapy as it did not measure post-treatment fertility. This study also did not compare differences in the two GnRHa formulations provided (goserelin and leuprorelin). Overall, adult female patients with breast cancer receiving chemotherapy with adjunct GnRHa have a reduced risk of POI than those receiving chemotherapy-only.

Click to read the study in JAMA Oncology

Relevant Reading: Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China

In-Depth [ randomized controlled trial]: This phase 3, open-label, randomized superiority clinical trial conducted at 2 hospital centres located in China randomly allocated 345 adult female patients with operable stage I to III breast cancer to receive chemotherapy with or without GnRHa and 330 were included in the primary analysis (n = 165 for each group). The primary outcome was POI measured at one year post-treatment with chemotherapy and was measured using AMH levels. A result of 0.5ng/mL or less was indicative of POI. Both OS and TFS were secondary outcomes. The mean (SD) AMH for the chemotherapy group receiving concurrent GnRHa was 1.84 (1.30) ng/mL while level for the chemotherapy-only group was 1.78 (1.10) (t = 0.476, P = 0.63). After removing 19 patients from the GnRHa group and 10 from the chemotherapy-only group who were identified as having AMH less than 0.5 ng/mL at study start, the difference in POI between the two groups was calculated. At one year, the mean (SD) AMH was 1.68 (1.29) mg/mL in the group receiving GnRHa and 1.04 (1.24) mg/mL in the chemotherapy-only group. A total of 15 patients in the GnRHa group and a total of 69 patients in the chemotherapy-only group were identified as having POI (absolute difference, 34.2%; OR, 0.231; 95% confidence interval (CI) 0.139-0.385; P<0.001). OS at 4 years in the GnRHa group was 96% while it was 97% in the chemotherapy-only group. TFS at 4 years was the same in both groups at 85%. No significant differences were found between the groups for either OS or TFS, however, when considering only patients under 35 years old, the GnRHa group had significantly better OS (100% vs 81%; P = 0.01) and TFS (93% vs 62%; P = 0.004) than the chemotherapy-only group.

RELATED REPORTS

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast CancerFemale Infertilitygnrha
Previous Post

The current understanding of spirituality in healthcare may be unclear

Next Post

Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

March 12, 2023
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Gastroenterology

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

March 8, 2023
#StudyGraphics: Adjuvant abemaciclib improves survival in patients  with hormone receptor-positive early breast cancer
StudyGraphics

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

March 8, 2023
Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses
Obstetrics

Low household income associated with worse outcomes for estrogen receptor-positive breast cancer

February 28, 2023
Next Post
Cervical cancer screening practices less cost-effective than suggested guidelines

Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer

Shorter hospital stays after hip fracture linked to greater risk of short-term death

Spinal anesthesia not superior to general anesthesia for hip surgery

Solitary kidney not associated with contrast-induced nephropathy

Accuracy of glomerular filtration rate estimation with use of Cystatin C

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options